Citius Pharmaceuticals is trading 5.1% up at $0.59 following a low-volume bounce that began in after-hours trading on July 9, 2026, despite a lack of new company-specific developments.
- The move appears disconnected from fresh earnings, FDA updates, financing, or major analyst actions.
- The price action likely reflects a continuation of speculative trading interest following prior updates on LYMPHIR commercialization and oncology progress.